Sunday, 3 March 2024


Simulations Plus targets early-stage tech investments By

EOG Resources Earnings Miss, Revenue Beats In Q2

© Reuters.

LANCASTER, Calif. – Simulations Plus , Inc. (NASDAQ:), a provider of modeling and simulation software for the pharmaceutical industry, announced its strategy to enhance corporate growth through strategic investments and partnerships with early-stage technology companies. This initiative is aimed at fostering innovation in computational biology and chemistry, as well as expanding the company’s total market opportunity.

The company’s investment objectives focus on adopting emerging technologies, such as artificial intelligence-driven drug design (AIDD), to enhance innovation. By seeding investments and forming partnerships, Simulations Plus aims to grow its mergers and acquisitions pipeline, thereby broadening its total addressable market. Additionally, the company intends to diversify its revenue streams through new software technology and scientific service partnerships, exploring new partner revenue models.

Will Frederick, CFO and COO of Simulations Plus, expressed enthusiasm for the initiative, stating that strategic acquisitions are a priority to complement organic growth and expand market presence. “This corporate development initiative is designed to allow us to reach into relevant technologies for immediate competitive benefit and long-term support of future acquisitions,” Frederick said.

Shawn O’Connor, CEO, highlighted the company’s position as a leader in simulation software and consulting services. “Many technologies used today were conceived and developed by early-stage companies, and we believe that partnering and investing in high-potential technologies will complement our R&D efforts and keep Simulations Plus at the forefront of innovation,” he said.

Simulations Plus, with over 25 years of experience, serves clients globally, offering solutions that integrate artificial intelligence/machine learning with various pharmacokinetic and pharmacodynamic modeling approaches. The company’s technology is widely licensed by major pharmaceutical, biotechnology, and regulatory agencies.

The information provided in this article is based on a press release statement from Simulations Plus, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Here to Read the Full Original Article at All News…